Skip to content
value.today

Flex Pharma, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2014
Total raised
$16 M
1 round on record
Latest round
$16 M
Jul 2014
First round on record
Jul 2014
Today
Went public
See the company page

Flex Pharma, Inc. is listed today as Decoy Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Flex Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$6 MPrivate placement after listing$2 to $10 million

Flex Pharma, Inc.: Private sale, May 2023

Investors in this round

1 investor had bought by the notice of May 25, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Flex Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$545,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Arthur · Executive Officer, Director · President, Chief Executive Officer, Director
  • Mark J. Rosenblum · Executive Officer · Chief Financial Officer
  • Arnold C. Hanish · Director
  • Bruce J. McCreedy · Director
  • Jonathan C. Lieber · Director
  • Paul C. Lammers · Director
  • Tess Burleson · Director
  • William K. McVicar · Director · Chair

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H. C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “In connection with the private placement, the placement agent received $545,000 and warrants to purchase up to 254,545 shares of Common Stock at an exercise price per share of $2.0625 per share.”
  • On the amounts: “Such amount would be $16,706,819 by including the aggregate exercise price due to the Company assuming full cash exercise of all warrants.”

Signed by Mark J. Rosenblum, Chief Financial Officer. Source: SEC Form D, newest notice filed May 25, 2023. Read the notice at the SEC.

equity, optionsSEC
Apr 2022$2 MPrivate placement after listing$2 to $10 million

Flex Pharma, Inc.: Private sale, Apr 2022

Investors in this round

4 investors had bought by the notice of May 5, 2022: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Flex Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$186,789
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Arthur · Executive Officer, Director · President, Chief Executive Officer, and Director
  • Mark J. Rosenblum · Executive Officer · Executive Vice President and Chief Financial Officer
  • Arnold C. Hanish · Director
  • Bruce J. McCreedy · Director
  • Jonathan J. Lieber · Director
  • Paul C. Lammers · Director
  • Tess K. Burleson · Director
  • William K. McVicar · Director · Chair

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co., Inc. (CRD 108604) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Ladenburg Thalman & Co. Inc. received the above sales commission in connection with the private placement of warrants.”
  • On the amounts: “The warrants and underlying shares of common stock include warrants to purchase 7,004,578 shares of common stock to certain institutional investors.”

Signed by Mark J. Rosenblum, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed May 5, 2022. Read the notice at the SEC.

optionsSEC
Jul 2014$16 MNo. 1$10 to $50 million

Flex Pharma, Inc.: Raise no. 1, Jul 2014

Investors in this round

20 investors had bought by the notice of Aug 6, 2014: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Flex Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $22 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christoph Westphal · Executive Officer, Director
  • Peter Barton Hutt · Director
  • Stephen Barton Kraus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christoph Westphal, President & CEO. Source: SEC Form D, newest notice filed Aug 6, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Flex Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (May 2023).

    SEC Form D · May 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2023

That is all the official record says: Flex Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Flex Pharma, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Flex Pharma, Inc.
InvestorKindAmountRoundRoleSource
Barbara Louise HibnerPersonnot statednot statedHeld Series A preferred stock (Form 3, 2025)SEC Form 3
Frederick Pierce IIPersonnot statednot statedHeld Series A preferred stock (Form 3, 2025)SEC Form 3
Longwood Fund II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Peter Barton HuttPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2015)SEC Form 3
Peter Klaus MarschelPersonnot statednot statedHeld Series A preferred stock (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 20 investors.

Largest shareholders today

Institutions holding Decoy Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Flex Pharma, Inc.
NameRoleNamed in
David J. ArthurPresident, Chief Executive Officer, DirectorMay 2023
Mark J. RosenblumChief Financial OfficerMay 2023
Christoph WestphalExecutive officerAug 2014
Arnold C. HanishDirectorMay 2023
Bruce J. McCreedyDirectorMay 2023
David J. ArthurPresident, Chief Executive Officer, DirectorMay 2023
Jonathan C. LieberDirectorMay 2023
Paul C. LammersDirectorMay 2023
Tess BurlesonDirectorMay 2023
William K. McVicarChairMay 2023
Jonathan J. LieberDirectorMay 2022
Tess K. BurlesonDirectorMay 2022
Christoph WestphalDirectorAug 2014
Peter Barton HuttDirectorAug 2014
Stephen Barton KrausDirectorAug 2014

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.